SOPHiA GENETICS SA (NASDAQ:SOPH) Receives $9.00 Consensus Target Price from Analysts

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have been assigned an average rating of “Hold” from the five ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $9.00.

Several equities analysts have recently commented on SOPH shares. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright began coverage on shares of SOPHiA GENETICS in a report on Monday, July 20th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st.

SOPHiA GENETICS Stock Down 5.5%

Shares of NASDAQ:SOPH opened at $5.72 on Thursday. The business’s 50 day moving average is $5.38 and its 200 day moving average is $5.07. The stock has a market cap of $479.85 million, a P/E ratio of -11.00 and a beta of 0.96. SOPHiA GENETICS has a 52-week low of $2.92 and a 52-week high of $6.77. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The firm had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million. Sell-side analysts predict that SOPHiA GENETICS will post -0.58 EPS for the current year.

Insider Transactions at SOPHiA GENETICS

In other news, CEO Ross Muken sold 9,838 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.22, for a total transaction of $51,354.36. Following the transaction, the chief executive officer directly owned 670,651 shares in the company, valued at approximately $3,500,798.22. This trade represents a 1.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Abhimanyu Verma sold 5,285 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $5.10, for a total transaction of $26,953.50. Following the transaction, the chief technology officer owned 192,171 shares in the company, valued at approximately $980,072.10. This represents a 2.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 176,711 shares of company stock worth $959,913. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC boosted its position in SOPHiA GENETICS by 66.2% during the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Principal Financial Group Inc. grew its stake in SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Archon Capital Management LLC grew its stake in SOPHiA GENETICS by 3.4% in the fourth quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after purchasing an additional 14,342 shares during the last quarter. Finally, Hodges Capital Management Inc. purchased a new position in SOPHiA GENETICS in the first quarter valued at about $2,157,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.